Austar Lifesciences Limited
AULSF
$0.02
-$0.05-71.43%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 109.39% | 233.87% | 152.06% | 128.12% | 114.03% |
| Total Depreciation and Amortization | -8.77% | -2.78% | 4.08% | 10.68% | 18.19% |
| Total Amortization of Deferred Charges | 4.67% | 2.38% | 0.77% | -2.63% | -6.01% |
| Total Other Non-Cash Items | 101.98% | -89.75% | -96.32% | -95.97% | -95.57% |
| Change in Net Operating Assets | 59.32% | 161.95% | 119.36% | 119.36% | 119.36% |
| Cash from Operations | 34.12% | 107.08% | 445.20% | 608.62% | 251.79% |
| Capital Expenditure | -12.75% | 18.97% | 34.78% | 57.67% | 70.86% |
| Sale of Property, Plant, and Equipment | -88.68% | 4.84% | 5,645.83% | 1,817.69% | 1,052.00% |
| Cash Acquisitions | -- | -0.51% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.67% | -52.78% | -54.50% | -20.23% | 34.07% |
| Cash from Investing | -397.39% | -92.01% | 35.80% | 91.14% | 107.92% |
| Total Debt Issued | 28.57% | 5.46% | -13.51% | -23.30% | -31.47% |
| Total Debt Repaid | -11.88% | -12.30% | -12.77% | -25.93% | -42.61% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 17.06% | 13.55% | 9.89% | 20.65% | 28.06% |
| Cash from Financing | 42.95% | -51.87% | -1,077.05% | -217.18% | -167.54% |
| Foreign Exchange rate Adjustments | -158.34% | -100.57% | 69.10% | 235.87% | 677.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,837.49% | 396.84% | 77.53% | -35.68% | -89.34% |